NASDAQ:ENTA
Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc.'s revenue fell 3.4% in fiscal 2025 to $65.3M while operating margin rose to −130.7%. Free cash flow was −$32.2M, −49.2% of revenue, and the diluted share count rose 0.8%.Summary generated from Enanta Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Nov 19, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$65.3M
Revenue growth−3.4%
Revenue, 5-yr CAGR−11.8%
Gross marginn/a
Operating margin−130.7%
Net margin−125.4%
ROICn/a
Return on equity−84.6%
Debt / equityn/a
Free cash flow−$32.2M
FCF margin−49.2%
Share count change+0.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 97 | 86 | 79 | 68 | 65 |
| Operating income | −110 | −124 | −137 | −122 | −85 |
| Net income | −79 | −122 | −134 | −116 | −82 |
| Free cash flow | −71 | −87 | −112 | −97 | −32 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 4Insider transaction report
Aug 10, 2026 - 8-KEntry into a material agreement
Jul 2, 2026 - 8-KOther events
Jun 23, 2026 - 8-KRegulation FD disclosure
Jun 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 11, 2026